Erratum: Vascular effects of aromatase inhibitors: Data from clinical trials (Journal of Steroid Biochemistry and Molecular Biology (2005) 95 (143-149) DOI: 10.1016/j.jsbmb.2005.04.005);Vascular effects of aromatase inhibitors: Data from clinical trials

Journal of Steroid Biochemistry and Molecular Biology

Volumn 95, Issue 1-5, 2005, Pages 143-149

  Howell, Anthony ^a   Cuzick, Jack ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; EXEMESTANE; GESTAGEN; LETROZOLE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANGINA PECTORIS; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DRUG EFFECT; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; STATISTICAL SIGNIFICANCE; STROKE; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

EID: 23744438916     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.11.003     Document Type: Erratum

References (34)

1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
2. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrole alone or on combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer Cancer 98 2003 1802 1810
3. R. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S.E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, A.S. Coates, E. Bajetta, D. Dodwell, R.E. Coleman, L.J. Fallowfield, E. Mickiewicz, J. Andersen, P.E. Lonning, G. Coccini, A. Stewart, N. Stuart, C.F. Snowdon, M. Carpentieri, G. Massimini, J.M. Bliss for the InterGroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N. Engl. J. Med. 350 2004 1081 1092
4. P. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, M.J. Piccart, M. Castiglione, D. Tu, L.E. Shepherd, K.I. Pritchard, R.B. Livingston, N.E. Davidson, L. Norton, E.A. Perez, J.S. Abrams, P. Therasse, M.J. Palmer, and J.L. Pater A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer N. Engl. J. Med. 349 2003 1793 1802
5. A. Buzdar, W. Jonat, A. Howell, S.E. Jones, C. Blomqvist, C.L. Vogel, W. Eirmann, J.M. Wolter, M. Azab, A. Webster, and P.V. Plourde Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group J. Clin. Oncol. 14 1996 2000 2011
6. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H.P. Sleebom, F. Jaenicke, A. Pluzanska, M. Dank, D. Becquart, P. Bapsy, E. Salminen, R. Snyder, H. Chaudri-Ross, R. Lang, P. Wyld, and A. Bhatnagar Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J. Clin. Oncol. 21 2003 2101 2109
7. A.M. Minino, E. Arias, K.D. Kochanek, S.L. Murphy, and B.L. Smith Deaths; final data for 2000 Natl. Vital Stat. Rep. 50 2002 1 120
8. C. Schairer, P.J. Mink, L. Carroll, and S.S. Devesa Probabilities of death from breast cancer and other causes among female breast cancer patients J. Natl. Cancer Inst. 96 2004 1311 1321
9. Writing Group for the Womens Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
10. The Womens Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Womens Health Initiative Randomized Trial JAMA 291 2001 1701 1712
11. K.S. Stamatelopoulos, J.P. Lekakis, N.A. Poulakaki, C.M. Papamichael, K. Venetsanou, K. Aznaouridis, A.D. Protogerou, T.G. Papaioannou, S. Kumar, and S.F. Stamatelopoulos Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women Am. Heart J. 147 2004 1093 1099
12. R.S. Braithwaite, R.T. Chlebowski, J. Lau, S. George, R. Hess, and N.F. Col Meta-analysis of vascular and neoplastic events associated with tamoxifen J. Gen. Intern. Med. 18 2003 937 947
13. S.E. Reis, J.P. Costantino, D.L. Wickerham, E. Tan-Chiu, J. Wang, and M. Kavanah Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial J. Natl. Cancer Inst. 93 2001 16 21
14. R.S. Blumenthal, B. Baranowski, and S.E. Dowsett Cardiovascular effects of raloxifene: the arterial and venous systems Am. Heart J. 147 2004 783 789
15. S. Martino, J.A. Cauley, E. Barrett-Connor, T.J. Powles, J.L. Mershon, D. Disch, R.J. Secrest, and S.R. Cummings CORE Investigators, Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: results from the Continuing Outcomes Relevant to Evista (CORE) trial J. Clin. Oncl. 22 14S 2004 Proc. ASCO, Abs. 1000, 97s
16. E. Barrett-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.A. Cox, K. Hoszowski, P. Rautaharju, K.D. Harper for the MORE investigators Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE randomized trial JAMA 287 2002 847 857
17. B. Thurlimann BIG 1-98: a prospective randomised double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Breast 14 Suppl. 1 2005 S3
18. R.C. Coombes The Intergroup Exemestane Study: a randomised trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen updated survival analysis Breast Cancer Res. Treat. 88 Suppl. 1 2004 S7
19. R.R. Love, D.A. Wiebe, J.M. Feyzi, P.A. Newcomb, and R.J. Chappell Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment J. Natl. Cancer Inst. 86 1994 1534 1539
20. L.D. Brun, C. Gagne, C. Rousseau, S. Moorjani, and P.J. Lupien Severe lipemia induced by tamoxifen Cancer 57 1986 2123 2126
21. J. Wojtacki, K. Lesniewski-Kmak, W. Pawlak, and E. Nowicka Anastrozole therapy and lipid profile: an update Eur. J. Cancer Suppl. 2 2004 142 Abs 297
22. J.M. Nabholtz, A. Buzdar, M. Pollack, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, and M. von Euler Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenipausal women: results of a North American multicenter randomized trial. Arimidex Study Group J. Clin. Oncol. 18 2000 3758 3767
23. J. Bonneterre, B. Thurlimann, J.F. Robertson, M. Krzakowski, L. Mauriac, P. Koralewski, I. Vergote, A. Webster, M. Steinberg, and M. von Euler Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study J. Clin. Oncol. 92 2001 2247 2258
24. J. Dewar, J. Nabholtz, J. Bonneterre, and A.U. Buzdar The effect of anastrozole ('Arimidex') on serum lipids: a randomised comparison of anastrozole (AN) vs. Tamoxifen (TAM) in postmenopausal women with advanced breast cancer Breast Cancer Res. Treat. 64 Suppl. 2000 S51 Abs. 164
25. M.S. Elisaf, E.T. Bairaktari, C. Nicolaides, B. Kakaidi, C.S. Tzallas, A. Katsaraki, and N.A. Pavlidis Effect of letrozole on the lipid profile in postmenopausal women with breast cancer Eur. J. Cancer 37 2001 1510 1513
26. T. Engen, J. Krane, D.C. Johannessen, P.E. Lonning, and S. Kvinnsland Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy Breast Cancer Res. Treat. 36 1995 287 297
27. G. Atalay, L. Dirix, L. Biganzoli, L. Beex, M. Nooij, D. Cameron, C. Lohrisch, T. Cufer, J.P. Lobelle, M.R. Mattiaci, M. Piccart, and R. Paridaens The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, "randomised phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients" Ann. Oncol. 15 2004 211 217
28. S. Sawada, and K. Sato Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer Breast Cancer Res. Treat. 82 Suppl. 1 2003 S31 S32
29. Y. Hozumi, Y. Hakamata, S. Ogura, and H. Nagai Effects of anastrozole on lipid metabolism compared with tamoxifen and torefimene in ovariectomised rats Breast Cancer Res. Treat. 76 2002 S98 Abs. 368
30. V. Kataja, P. Hietanen, H. Joensuu, T. Ala-Luhtala, R. Asola, R. Kokko, and K. Holli The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study Breast Cancer Res. Treat. 76 2002 S156 Abs. 634
31. J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, and P. Boyle Overview of the main outcomes in breast cancer prevention trials Lancet 361 2003 296 300
32. M.A. Espeland, S.R. Rapp, S.A. Shumaker, R. Brunner, J.E. Manson, B.B. Sherwin, J. Hsai, K.L. Margolis, P.E. Hogan, R. Wallace, M. Dailey, R. Freeman, J. Hayes for the Womens Health Initiative Memory Study Investigators Conjugated equine estrogens and global cognitive function in postmenopausal women. Womens Health Initiative Memory Study JAMA 291 2004 2959 2968
33. S.A. Shumaker, C. Legault, L. Kuller, S.R. Rapp, L. Thal, D.S. Lane, H. Fillit, M.L. Stefanick, S.L. Hendrix, C.E. Lewis, K. Masaki, L.H. Coker for the Womens Health Initiative Memory Study Investigators Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Womens Health Initiative Memory Study JAMA 291 2004 2947 2958
34. K. Yaffe, K. Krueger, S. Sarkar, D. Grady, E. Barrett-Connor, D.A. Cox, T. Nickelson for the multiple outcomes of Raloxifene Evaluation Investigators N. Engl. J. Med. 344 2001 1207 1213